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Previewsunderlying rationale exists where miRNA
depletion causes particular proliferative
or survival advantages in these cancers.
Indeed, it seems rather mysterious that
a pathway that is considered important
to provide robustness to gene expression
programs would display itself so little
robustness to mutational assault. It will
therefore be of particular interest to
examine whether haploinsufficiency is
a general feature of miRNA pathway
genes across various cancer sites and
types or more closely restricted to MSI+
tumors.
Finally, it remains to be seen whether
the new findings can be exploited thera-
peutically. At this point, short of gene
therapy, there seems to be little that can
be done to target the XPO5 defect directly
so that restoring miRNA accumulation by
alternative routes might be a more real-istic approach. Provided that only one or
few of the deregulated miRNAs are
responsible for the tumor-promoting
effect of XPO5 mutation, it may be
possible to supply them exogenously as
miRNA duplexes that would not need to
undergo nuclear export. Alternatively, it
may be possible to identify a subset of
key targets of the deregulated miRNAs
that might be amenable to inactivation
through classical pharmacological
approaches or novel biologics.
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T cell precursor malignancies may present as T-lymphoblastic lymphoma (T-LBL) with marked enlargement
of lymph nodes or acute T-lymphoblastic leukemia (T-ALL) with little lymph node enlargement. In this issue
of Cancer Cell, Feng et al. show that dysregulation of BCL2, AKT signaling, and cell adhesion pathways are
hallmarks of T-LBL.T-lineage lymphoblastic lymphoma (T-
LBL) and acute lymphoblastic leukemia
(T-ALL) represent up to 15%–25% of
cases of ALL in children and adults and
exhibit a remarkable spectrum of clinical,
pathologic, and genetic features. In
contrast to B-progenitor ALL, in which
extensive bone marrow involvement at
presentation is a near universal feature
and significant lymph node enlargement
is uncommon, patients with T-lineage
disease frequently present with marked
lymph node enlargement in the chest
(mediastinal masses), often with minimal
or absent bone marrow involvement
(Figure 1). Traditionally, patients witha mediastinal mass and less than 25%
leukemic cells (blasts) in the bone marrow
are deemed to have T-LBL; those with
a high marrow burden, T-ALL. While this
distinction may appear somewhat arbi-
trary, a notable observation is that
patients with large mediastinal masses
frequently exhibit little, if any, evidence
of tumor dissemination and marrow
involvement, and the basis for this is
unknown.
Both T-LBL and T-ALL cases com-
monly harbor chromosomal rearrange-
ments, submicroscopic DNA copy num-
ber alterations, and sequence mutations.
These alterations commonly dysregulateor disrupt genes with key roles in hemato-
poietic development, lymphoid differenti-
ation, cell cycle regulation, and tumor
suppression and are key events in leuke-
mogenesis (e.g., rearrangements of
T cell antigen receptor genes, HOX11L1
and HOX11L2, TAL1, LYL1, mutation of
NOTCH1 and FBXW7, and deletion or
mutation of PTEN and WT1) (Aifantis
et al., 2008). However, in contrast to
B-progenitor ALL, in which specific
genetic alterations such as mutation of
the lymphoid transcription factor IKZF1
are strongly associated with poor prog-
nosis (Mullighan et al., 2009), identifica-
tion of features that predict clinical, October 19, 2010 ª2010 Elsevier Inc. 297
Figure 1. Chest Radiograph Showing
a Mediastinal Mass, Indicated by an Arrow,
in T-Lineage Lymphoblastic Lymphoma
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Previewsfeatures, behavior, or outcome in T-
lineage disease has been frustratingly
difficult. Peripheral blood leukocyte
count, early responsiveness to therapy
(Campana, 2010), and aberrant ‘‘early
thymic progenitor’’ immunophenotype
are associated with poor outcome (Cou-
stan-Smith et al., 2009), but associations
between individual genetic alterations
and clinical features are, at best, weak
(Karrman et al., 2009). Several studies
have compared and contrasted clinical
features and genetic alterations between
T-LBL and T-ALL (reviewed in Burkhardt,
2010). While several differences have
been reported, such as somewhat higher
relapse rate in T-ALL, these differences
are often subtle. Similarly, several studies
have examined differences in cytogenetic
alterations and submicroscopic genetic
alterations in ALL, with no unique alter-
ations in either T-ALL or T-LBL identified.
Intriguingly, gene expression profiling has
identified differences in expression of cell
adhesion, cell cycle, and apoptosis genes
between the two diseases, but the mech-
anistic basis of these differences has not
been determined (Raetz et al., 2006).
In the current issue, Feng, Look, and
colleagues have used a zebrafish model
of T-LBL/ALL to investigate the basis of
this dichotomy (Feng et al., 2010). Both
T-ALL and T-LBL cells commonly harbor
activating mutations of NOTCH1 (Weng
et al., 2004), which result in activation of
MYC-regulated transcriptional networks
(Palomero et al., 2006). In the current
study, the authors used a transgenic298 Cancer Cell 18, October 19, 2010 ª2010Myc-driven zebrafish model of T-LBL, in
which fish expressing Myc and Bcl2
exhibited an increased penetrance and
reduced latency of T-LBL than did fish
transgenic for Myc alone. The authors
found that while T-lineage disease devel-
oped in both Myc:Bcl2- and Myc-only
fish, there was little systemic dissemina-
tion from Myc:Bcl2 T-LBL, either from
theprimary tumors or after transplantation
into secondary recipients. The Bcl2-ex-
pressing tumors also had a survival
advantage and the propensity to form
aggregates in long-term culture. Careful
examination of the tumors showed local
invasion in the Myc:Bcl2 tumors, but
a notable lack of vascular invasion.
The authors also observed increased
BCL2 expression in primary human
T-LBL, but not T-ALL samples, thus impli-
cating BCL2 expression as an important
determinant of the behavior of T-lineage
disease. To investigate the underlying
mechanism, the authors examined the
ultrastructural and signalingcharacteristics
of their tumors. They observed evidence of
autophagy in both fish and human T-LBLs,
but no evidence of dissemination in T-LBL
fish treated with the autophagy inhibitor
chloroquine, indicating that while autoph-
agy may be a hallmark of T-LBL, it is not
a critical determinant of dissemination. As
AKT activation has been implicated in
T cell migration and suppression of
autophagy, the authors examined AKT
activation in their tumors and noted mark-
edly higher levels of phosphorylation of
Ser473 of Akt, indicating Akt activation, in
T-LBL tumors that disseminated. Introduc-
tion of myristoylated, constitutively active
Akt2 accelerated tumorigenesis and
dissemination in Myc:bcl2 tumors and in-
hibited in vitro aggregate formation,
implicating Akt signaling in the ability to
disseminate.
While these findings suggest a role of
BCL2 in influencing tumor behavior in
T-lineage leukemia, they do not directly
explain why Bcl2-overexpressing tumors
display a singular lack of vascular inva-
sion and dissemination. To further
address this, the authors examined pub-
lished gene expression profiling data
comparing human T-ALL and T-LBL
(Raetz et al., 2006). This analysis failed
to detect enrichment of leukocyte adhe-
sion and migration gene sets in human
T-LBL but did identify increased expres-
sion of the adhesion molecule sphingo-Elsevier Inc.sine-1-phosphate receptor 1 (S1PR1, or
S1P1) and the adhesion molecule (and
putative downstream target of S1PR1)
ICAM1. S1PR1 expression was noted to
be high in human T-LBL cells and imma-
ture cortical thymocytes in normal thymi,
but low in more mature thymocytes in
the thymic medulla and human T-ALL
cells. As S1PR1 signaling has been
reported to promote T cell adhesion and
inhibit thymocyte emigration, this sug-
gested a possible mechanism for reten-
tion of T-LBL cells in the thymus. Accord-
ingly, the authors observed increased
intravasation of T-LBL cells treated with
the S1PR1 inhibitor W416.
Together, these data provide an impor-
tant advance in our understanding of the
biology of T-LBL. The results of Feng
et al. (2010) strongly suggest that the
accumulation of lymphoblasts in medias-
tinal masses is at least in part determined
by the activation of signaling and adhe-
sion pathways that inhibit the intravasa-
tion and subsequent dissemination of
leukemic cells. This elegant model has
proven highly informative but leaves
several important questions to be
answered in future studies. While the
data for increased expression of BCL2,
reduced activation of AKT, and activated
S1PR1 signaling in both fish and human
T-LBL are compelling, the nature of the
upstream events dysregulating and link-
ing these pathways is unknown. Existing
genetic and genomic analyses have failed
to identify alterations unique to T-LBL,
and the nature of the genetic or epigenetic
events activating these pathways are
unclear. As the expression of S1PR1 by
T-LBL cells is similar to that of immature
cortical thymocytes, it is possible that
the phenotype of T-LBLmay in part reflect
maturational stage, although this is not
supported by differences in immunophe-
notype between T-LBL and T-ALL in
clinical samples. Moreover, the mecha-
nisms responsible for activation of BCL2
expression and aberrant AKT activation
in T-LBL remain unclear. It is likely that
future studies interrogating the genomic
alterations in T-LBL in greater detail will
provide important additional insights into
this disease. However, the current study
represents an important advance and
raises the possibility that therapeutic inhi-
bition of BCL2 and AKT may be beneficial
in patients with the lymphomatous form of
this disease.
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Avoiding the inhibitory effects of p53 on cell growth is important for tumor progression. In this issue ofCancer
Cell, Picchiorri et al. describe epigenetic silencing of MDM2-targeting microRNAs in multiple myeloma (MM),
which generally appears to have intact p53 function. This provides the rationale for microRNA-targeted
therapy for MM.Genetically,multiplemyeloma (MM)canbe
divided into tumorswith recurrent immuno-
globulinheavychaingene translocationsor
hyperdiploidy. Superimposed on this are
a variety of presumably secondary genetic
events, including activating mutations of
Ras, rearrangements of Myc, mutations
thatactivate theNFkBpathway,and late in-
activatingmutations of p53 (Fonseca et al.,
2009). As noted by Pichiorri et al., (2010),
mutations of p53 are rare in untreated
MM and the tumors appear to have intact,
if perhaps suppressed, p53 function, sug-
gesting that therapeutic modulation of the
p53/MDM2 pathway holds promise to
help the majority of patients.
Deletion of one copy of p53 by FISH has
been uniformly found to be an adverse
prognostic factor with all therapies used
in the treatment of MM: alkylating agents,
proteasome inhibitors, and immune
modulator-based therapies (Lode’ et al.,
2010; Kapoor et al., 2010). In contrast
to patients with other poor-prognosticgenetic lesions [e.g., t(4;14)], patients
with deletion of p53 have seen less
improvement in their survivalwith theaddi-
tion of proteasome inhibitors and immune
modulators. Nevertheless, data concern-
ing loss of heterozygosity of p53 due to
deletion of chromosome 17p and/or p53
mutation in MM have been confusing,
perhapsat least inpartbecauseofold liter-
ature based on the analysis of unpurified
bone marrow samples. In an analysis of
CD138-purified myeloma cells from 716
patients, deletion of one copy of p53
was detected by FISH in 3% of MGUS
(monoclonal gammopathy of undeter-
mined significance), 1% of SMM (smol-
dering multiple myeloma), and 10% of
MM (Chiecchio et al., 2009). There is a
paucity of data on patients at the time of
relapse; however, in another recent study,
deletionof p53wasseen in 56%ofprimary
plasma cell leukemia and 83%of themore
aggressive secondary plasma cell
leukemia (Tiedemann et al., 2008).Somewhat surprising, given the
strong correlation between loss of one
copy of p53 deletion and survival, is
the fact that in a cohort of 92 untreated
MM patients, only 37% of patients with
p53 deletions by FISH were found
to have mutations on the remaining allele,
although all those with mutations were
found to also have p53 deletions (Lode’
et al., 2010). It would be very informative
to characterize whether in terminal
samples from patients that initially pre-
sented with a 17p deletion by FISH,
a p53 mutation has emerged under the
selective pressure of therapy and disease
progression. In the absence of such
a study, we can examine the status of
p53 in a panel of human MM cell lines
derived from patients at the very end
stages of the disease. It is notable that
the majority of MM cell lines have p53
mutation (Mazars et al., 1992). Although
one has to consider that cell lines have
been under the selective pressure of being, October 19, 2010 ª2010 Elsevier Inc. 299
